Adrian Quartel
Chief Tech/Sci/R&D Officer at ZEVRA THERAPEUTICS, INC.
Profile
Adrian Quartel is currently the Chief Medical Officer at Zevra Therapeutics, Inc. He previously worked as the Head-Medical Affairs at BioMarin Pharmaceutical, Inc. from 2017 to 2020, as the Chief Medical Officer at Adamas Pharmaceuticals LLC from 2020 to 2022, and as the Chief Medical Officer at Acer Therapeutics, Inc. from 2022 to 2023.
Dr. Quartel holds a doctorate degree from Erasmus University Rotterdam and a graduate degree from The Royal College of Physicians.
Adrian Quartel active positions
| Companies | Position | Start |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2024-01-03 |
Former positions of Adrian Quartel
| Companies | Position | End |
|---|---|---|
| ACER THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 2022-12-31 |
| ADAMAS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2022-01-31 |
| BIOMARIN PHARMACEUTICAL INC. | Chief Tech/Sci/R&D Officer | 2020-08-31 |
Training of Adrian Quartel
| Erasmus University Rotterdam | Doctorate Degree |
| The Royal College of Physicians | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| ZEVRA THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Acer Therapeutics, Inc.
 Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |
- Stock Market
- Insiders
- Adrian Quartel
